Type 2 diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Treatment - Drugs
Placebo
Sponsors
Vice chancellor of Research, Tehran University of Medical Sciences, Dr. Masoud Younesian
Diabetes Research Center, Endocrinology and Metabolism Research Institute
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Ability to give informed consent; Age 40-60 years; Diabetic patients with BMI less than 35 kg/m2; Lack of insulin therapy; HbA1c > 7.5. Exclusion criteria: Subjects on any antioxidant medication; Patient on non-steroidal anti-inflammatory drug; Patients on insulin therapy; Patients with severe diabetic complications such as nephropathy , retinopathy and amputation; On any agent with significant antioxidant properties; History of alcohol abuse; Any life threatening disease such as cancer and infectious diseases; Allergy to peanuts, grapes, wine, mulberries; Pregnant women; Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks; Subjects on anticoagulants; History of recent taking red grapes, pistachios, almonds and berries; ALT and/or AST > 2 times above upper limit of normal.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent of CD14+ ? CD16+ cells. Timepoint: Before and after two months of intervention. Method of measurement: Flow cytometry.;FBS. Timepoint: Before and after two months of intervention. Method of measurement: Enzymatic reaction.;HbA1c. Timepoint: Before and after two months of intervention. Method of measurement: HPLC. | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL. Timepoint: Before and after two months of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: Before and after two months of intervention. Method of measurement: Spectrophotometry.;TG. Timepoint: Before and after two months of intervention. Method of measurement: Spectrophotometry.;Cholesterol. Timepoint: Before and after two months of intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: Before and after two months of intervention. Method of measurement: ELISA kit.;Insulin resistance. Timepoint: Before and after two months of intervention. Method of measurement: HOMA-IR.;CRP. Timepoint: Before and after two months of intervention. Method of measurement: Autoanalyzer.;AST. Timepoint: Before and after two months of intervention. Method of measurement: Autoanalyzer.;ALT. Timepoint: Before and after two months of intervention. Method of measurement: Autoanalyzer.;BMI. Timepoint: Before and after two months of intervention. Method of measurement: Body weight(Kg)/height(m2).;Systolic and diastolic blood pressure. Timepoint: Before and after two months of intervention. Method of measurement: Mercury sphygmomanometer.;Creatinine. Timepoint: Before and after two months of intervention. Method of measurement: Autoanalyzer.;Urea. Timepoint: Before and after two months of intervention. Method of measurement: Autoanalyzer.;TNF-a. Timepoint: Before and after two months of intervention. Method of measurement: ELISA.;IL-6. Timepoint: Before and after two months of intervention. Method of measurement: ELISA.;MCP-1. Timepoint: Before and after two months of intervention. Method of measurement: ELISA.;IL-10. Timepoint: Before and after two months of intervention. Method of measurement: ELISA.;Expression of SIRT1. Timepoint: Before and after two months of intervention. Method of measurement: Real-time PCR.;Expression of TLR2. Timepoint: Before and after two months of intervention. Method of measurement: Real-time PCR.;Expression of TLR4. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHadi Khodabandehloo
Tehran University of Medical Sciences
Outcome results
None listed